Pharmaceutical Business Review

Eisai's Lenvima gets FDA breakthrough status for renal cell carcinoma Pharmaceutical Business Review The US Food and Drug Administration (FDA) has granted breakthrough therapy designation for Eisai's in-house developed new anticancer agent Lenvima (lenvatinib mesylate, lenvatinib) for the potential indication of advanced and/or metastatic renal cell ... Eisai's Lenvima receives Breakthrough Therapy designation for renal cell carcinoma European Pharmaceutical Review FDA grants breakthrough drug designation to Lenvima for advanced RCC Healio Eisai's Lenvima breakthrough therapy for new indication PharmaTimes all 8 news articles »

...